Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNA3 | P22001 | 1/20 | 0.38 |
| ▸ | PRKCQ | Q04759 | 1/20 | 0.38 |
| ▸ | FLT3 | P36888 | 1/20 | 0.37 |
| ▸ | HTR2C | P28335 | 2/20 | 0.35 |
| ▸ | HTR2B | P41595 | 2/20 | 0.35 |
| ▸ | SOS1 | Q07889 | 1/20 | 0.35 |
| ▸ | PDE5A | O76074 | 1/20 | 0.35 |
| ▸ | APP | P05067 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3534567 | 1.00 | KCNA3 (0.38) | KCNA3PRKCQFLT3HTR2CHTR2B | |
| SCHEMBL3536969 | 0.91 | FLT3 (0.43) | KCNA3PRKCQFLT3PDE5A | |
| SCHEMBL3536972 | 0.91 | FLT3 (0.43) | KCNA3PRKCQFLT3PDE5A | |
| SCHEMBL3537203 | 0.91 | HTR3A (0.42) | KCNA3FLT3HTR2CHTR2BSOS1 | |
| SCHEMBL3537697 | 0.85 | FLT3 (0.41) | PRKCQFLT3SOS1APP | |
| SCHEMBL3537700 | 0.85 | FLT3 (0.41) | PRKCQFLT3SOS1APP | |
| SCHEMBL3542520 | 0.83 | EGLN1 (0.40) | PRKCQFLT3SOS1PDE5AAPP | |
| SCHEMBL3542517 | 0.83 | EGLN1 (0.40) | PRKCQFLT3SOS1PDE5AAPP | |
| SCHEMBL3537419 | 0.81 | PDE5A (0.47) | FLT3PDE5AAPP | |
| SCHEMBL3537416 | 0.81 | PDE5A (0.47) | FLT3PDE5AAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7829566-B2 | Such as (7-chloro-2-styryl-quinazolin-4-yl)-(3-imidazol-1-yl-propyl)-amine; glycoprotein antagonist; anticholesterol agents; cardiovascular disorders; strokes; antiischemic agents | MEDERSKI WERNER | 2010-11-09 | — | — | US | disclosed |
| US-20070293667-A1 | 4-Amino-quinazolines | MEDERSKI WERNER | 2007-12-20 | — | — | US | disclosed |
| WO-2004030671-A2 | USE OF 4-AMINO-QUINAZOLINES AS ANTI CANCER AGENTS | MERCK PATENT GMBH (DE) | 2004-04-15 | — | — | WO | disclosed |
| US-20040044204-A1 | 4-amino-quinazolines | ORTHO-MCNEIL PHARMACEUTICALS, INC. | 2004-03-04 | — | — | US | disclosed |
| EP-1318985-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GmbH (DE) | 2003-06-18 | — | — | EP | disclosed |
| WO-2002024666-A2 | 4-AMINO-QUINAZOLINES | MERCK PATENT GMBH (DE) | 2002-03-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040044204-A1 | 4-amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | KCNA3 457/4885PRKCQ 4007/4885FLT3 493/4885 |
| US-20070293667-A1 | 4-Amino-quinazolines | MRGPRX4, MRGPRX1, MRGPRX2 | KCNA3 579/4885PRKCQ 4185/4885FLT3 224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.